Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Brandon Folkes
HC

Brandon Folkes

H.C. Wainwright
Wall Street Analyst
★★☆☆☆
#2820
on 13Foresight · ranked by our own returns
37%
Success Rate
-4.0%
Average Return
50 of 136 calls profitable · -6.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 37% of Brandon Folkes's ratings turned a profit when each position was held for 2 year — averaging -4.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

221 Buy 4 Hold 0 Sell
Brandon's Stock Coverage 46 ratings · 2026-11-08
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return vs S&P 500 ⓘ
PYPD
PolyPid
 Oct 29, 2026 BUY Strong Buy
+191.5% avg upside
7 analysts
$13.00
141.10% Upside
 -0.2% ·
CNTB
Connect Biopharma Holdings
 Oct 28, 2026 BUY Strong Buy
+718.8% avg upside
12 analysts
$7.00
772.50% Upside
 -5.1% ·
DERM
Journey Medical Corp
 Oct 26, 2026 BUY Strong Buy
+132.2% avg upside
11 analysts
$13.00
151.47% Upside
 -3.6% ·
ACHV
Achieve Life Sciences
 Oct 23, 2026 BUY Strong Buy
+128.6% avg upside
16 analysts
$12.00
75.62% Upside
 +5.2% ·
SGMT
Sagimet Biosciences, Inc. Class A
 Oct 22, 2026 BUY Strong Buy
+194.3% avg upside
17 analysts
$29.00
192.34% Upside
 -1.6% ·
TSE:EPRX
Eupraxia Pharmaceuticals
 Oct 20, 2026 BUY Strong Buy
+122.3% avg upside
11 analysts
$15.36
61.28% Upside
 -11.2% ·
OMER
Omeros
 Oct 16, 2026 BUY Buy
+13.6% avg upside
14 analysts
$33.00
78.88% Upside
 +12.8% ·
RANI
Rani Therapeutics Holdings
 Oct 06, 2026 BUY Strong Buy
+1444.2% avg upside
10 analysts
$11.00
1764.31% Upside
 -28.8% ·
ENTA
Enanta Pharmaceuticals
 Sep 23, 2026 BUY Buy
+206.4% avg upside
17 analysts
$20.00
86.79% Upside
 -15.7% ·
TSE:CRDL
Cardiol Therapeutics
 Sep 21, 2026 BUY Strong Buy
+637.3% avg upside
7 analysts
$12.57
675.87% Upside
 -38.6% ·
VALN
Valneva
 Sep 21, 2026 BUY Strong Buy
+106.8% avg upside
6 analysts
$18.00
230.28% Upside
 -12.8% ·
MNKD
MannKind
 Sep 21, 2026 BUY Buy
+104.0% avg upside
22 analysts
$10.00
185.62% Upside
 +11.4% ·
TLPH
Talphera
 Sep 21, 2026 BUY Buy
+357.5% avg upside
15 analysts
$3.00
191.22% Upside
 -10.3% ·
MIST
Milestone Pharmaceuticals
 Sep 21, 2026 BUY Strong Buy
+910.3% avg upside
8 analysts
$8.00
995.97% Upside
 -19.4% ·
TRVI
Trevi Therapeutics
 Sep 21, 2026 BUY Strong Buy
+75.4% avg upside
18 analysts
$24.00
77.09% Upside
 -14.0% ·
XERS
Xeris Pharmaceuticals
 Sep 21, 2026 BUY Strong Buy
+3.9% avg upside
10 analysts
$10.00
6.64% Downside
 -6.9% ·
RNTX
Rein Therapeutics
 Sep 21, 2026 BUY Strong Buy
+1188.1% avg upside
6 analysts
$8.00
1093.99% Upside
 -22.8% ·
COLL
Collegium Pharmaceutical
 Sep 21, 2026 BUY Strong Buy
+77.4% avg upside
10 analysts
$60.00
152.08% Upside
 +2.7% ·
ZVRA
Zevra Therapeutics
 Sep 21, 2026 BUY Strong Buy
+113.0% avg upside
15 analysts
$26.00
152.94% Upside
 -0.7% ·
ANIP
ANI Pharmaceuticals
 Sep 21, 2026 BUY Strong Buy
+40.0% avg upside
12 analysts
$121.00
67.97% Upside
 -12.5% ·
TRAW
Traws Pharma
 Aug 18, 2026 HOLD Buy
+10541.9% avg upside
10 analysts
$1.00
237.88% Upside
 -55.6% ·
HRTX
Heron Therapeutics
 Aug 17, 2026 HOLD Strong Buy
+10208.0% avg upside
21 analysts
 — -7.8% ·
PTHS
Pelthos Therapeutics
 Aug 14, 2026 BUY Strong Buy
+396.3% avg upside
8 analysts
$60.00
538.33% Upside
 -66.0% ·
CRMD
Cormedix
 Aug 14, 2026 BUY Strong Buy
+165.8% avg upside
13 analysts
$13.00
128.33% Upside
 -30.6% ·
SINT
Sintx Technologies
 Aug 13, 2026 BUY Strong Buy
+383.1% avg upside
8 analysts
$10.00
488.24% Upside
 -8.8% ·
INDV
Indivior
 Aug 04, 2026 BUY Strong Buy
+1.0% avg upside
10 analysts
$48.00
35.74% Upside
 -0.6% ·
ADIL
Adial Pharmaceuticals
 Mar 04, 2025 BUY Strong Buy
+793.9% avg upside
7 analysts
$200.00
3860.46% Upside
 -78.4% ·
RMTI
Rockwell Med
 Nov 14, 2024 BUY Buy
+93.1% avg upside
11 analysts
$5.00
29.31% Downside
 · ·
EBS
Emergent Biosolutions
 Aug 22, 2024 BUY Buy
+267.1% avg upside
9 analysts
$16.00
135.00% Upside
 -46.5% ·
CERS
Cerus
 May 03, 2024 BUY Strong Buy
+135.8% avg upside
10 analysts
$4.00
75.47% Upside
 +67.9% ·
ELUT
Elutia
 May 12, 2023 BUY Strong Buy
+867.6% avg upside
5 analysts
$10.00
1094.69% Upside
 -21.6% ·
OBSEF
ObsEva
 Mar 17, 2023 HOLD Buy
+10799900.0% avg upside
8 analysts
 — · ·
IMVIF
IMV
 Mar 17, 2023 HOLD Buy
+2452638975.0% avg upside
7 analysts
 — · ·
EGRX
Eagle Pharmaceuticals
 Mar 13, 2023 HOLD Strong Sell
+2531.5% avg upside
2 analysts
$33.00
3373.66% Upside
 · ·
VERU
Veru
 Feb 09, 2023 BUY Strong Buy
+838.3% avg upside
11 analysts
$15.00
585.01% Upside
 -85.9% ·
R
Ryder System
 Feb 03, 2023 BUY Strong Buy
-16.0% avg upside
15 analysts
$48.00
83.09% Downside
 +67.7% ·
RDHL
RedHill Biopharma
 Nov 22, 2022 BUY Strong Buy
+5057.3% avg upside
7 analysts
$40.00
10214.63% Upside
 · ·
SRNE
Sorrento Therapeutics
 Nov 02, 2022 BUY Strong Buy
+8333233.3% avg upside
7 analysts
$5.00
1666566.65% Upside
 · ·
TRVN
Trevena
 Mar 31, 2022 BUY Buy
+128278.4% avg upside
11 analysts
$50.00
450350.53% Upside
 · ·
ALKS
Alkermes
 Jan 27, 2022 BUY Strong Buy
-3.4% avg upside
34 analysts
$32.00
29.45% Downside
 +13.0% ·
AXGN
AxoGen
 Nov 04, 2021 BUY Strong Buy
-17.4% avg upside
21 analysts
$25.00
49.46% Downside
 -69.4% ·
JAZZ
Jazz Pharmaceuticals
 Oct 06, 2021 BUY Strong Buy
+16.2% avg upside
36 analysts
$210.00
2.87% Downside
 -5.8% ·
VRAYQ
Viewray
 Aug 09, 2021 BUY Buy
+558333233.3% avg upside
12 analysts
$8.00
799999900.04% Upside
 · ·
SMTI
Sanara MedTech
 Jun 30, 2021 BUY Buy
+19.4% avg upside
5 analysts
$45.00
37.08% Upside
 +8.5% ·
SIBN
SI-Bone
 Dec 15, 2020 BUY Strong Buy
+22.7% avg upside
18 analysts
$33.00
55.51% Upside
 -54.2% ·
PAHC
Phibro Animal Health
 Sep 12, 2016 BUY Hold
+0.0% avg upside
10 analysts
$30.00
22.89% Downside
 +73.2% ·
🔒 41 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Brandon Folkes — Frequently Asked Questions
How accurate are Brandon Folkes's stock ratings?
Based on the calls 13Foresight could measure, about 37% of Brandon's ratings were profitable over a one-year hold, with an average return of -4.3% per rating, or -5.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Brandon ranked on 13Foresight?
Brandon Folkes is currently ranked #2820 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Brandon cover?
Brandon most recently has ratings on PYPD, CNTB, DERM, ACHV, SGMT, TSE:EPRX, OMER, RANI, ENTA, TSE:CRDL, VALN, MNKD and 34 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.